

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5215		Application No. 10/554,202	
RESUBMISSION OF PTO Form 1449 December 4, 2008				Applicants: Robert Hugh BRADBURY <i>et al.</i>			
				Filing Date: October 24, 2005		Group Art Unit: 1624	

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1. US 2003/0186995	October 2, 2003	Kath et al.				
	2. US 2004/0048880	March 11, 2004	Himmelsbach et al.				
FOREIGN PATENT DOCUMENTS							
	Document No.	Date	Country	Inventor/Assignee	Translation		
	3. CA 2476008	October 9, 2003	Canada	Boehringer Ingelheim Pharma			
	4. CA 2543649	May 12, 2005	Canada	Boehringer Ingelheim International GmbH			
	5. WO 01/21596	March 29, 2001	WIPO	AstraZeneca AB			
	6. WO 2004/046101	June 3, 2004	WIPO	Array Biopharma Inc.			
	7. WO 2005/041973	May 12, 2005	WIPO	Boehringer Ingelheim International GmbH			
	8. WO 2005/097134	October 20, 2005	WIPO	The Scripps Research Institute			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	9. Ballard et al. "Developing a small molecule erbB2 inhibitor: challenges with optimising DMPK properties" Poster - Presented at DMDG Cambridge (February 6, 2008)						
	10. Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007)						
	11. Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008)						
	12. Barlaam et al. "Indazolyamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-activity relationships and identification of a candidate drug" at AACR in 2007						
	13. Barlaam et al. "Neutral 5-substituted 4-indazolyaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008)						
	14. Barlaam et al. "Indazolyamino/Anilinoquinazolines Bearing a C-5 Substitution As erbB2 Kinase Inhibitors: Structure-Activity Relationships and Identification of a Candidate Drug" Poster number P044, presented at XXth International Symposium of Medicinal Chemistry (EFMC-ISM-C 2008), Vienna, Austria, August 31 - September 4, 2008						
	15. Cockerill et al. "Indazolyamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001)						
	16. Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008)						
	17. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003)						
	18. Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006						
	19. Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006)						
	20. Jani et al. "Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor" Cancer Research 67(20):9887-9893 (2007)						
Examiner			Date Considered				

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

Application No.
10/554,202

RESUBMISSION OF

PTO Form 1449
December 4, 2008

Group Art Unit: 1624

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
---------	--------------	------	------	-------	-----------	-------------

		Document No.	Date	Country	Class	Sub-Class	Translation
--	--	--------------	------	---------	-------	-----------	-------------

21. Klutichko et al. "Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinoipyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors" J Med Chem. 49(4):1475-1485 (2006)
22. Petrov et al. "Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series" Bioorg Med Chem Lett. 16(17):4686-4691 (2006)

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

056291-5215

10/554.202

Applicants: **BRADBURY** *et al.*

Filing Date: October 24, 2005

Group Art Unit: 1624

RESUBMISSION OF

PTO Form 1449

June 8, 2007

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	US 4,335,127	June 15, 1982	Vandenberk et al.			
2.	US 4,921,863	May 1, 1990	Sugimoto et al.			
3.	US 6,297,258	October 2, 2001	Wissner et al.			
4.	US 6,562,319	May 13, 2003	Mishani et al.			
5.	US 6,972,288	December 6, 2005	Himmelsbach et al.			
6.	US 20020082270	June 27, 2002	Himmelsbach et al.			
7.	US 20020128553	September 12, 2002	Mishani et al.			
8.	US 20040176361	September 9, 2004	Fujio et al.			

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Inventor/Assignee	Translation
9.		EP 0288563	November 2, 1988	EPO	Eisai Co., Ltd.	
10.		EP 1230919	August 14, 2002	EPO	Warner-Lambert Company	
11.		EP 1369418	December 10, 2003	EPO	Mitsubishi Pharma Corporation	
12.		WO 88/02365	April 7, 1988	WIPO	Eisai Co., Ltd.	US 4,921,863
13.		WO 99/06378	February 11, 1999	WIPO	Warner-Lambert Company	
14.		WO 00/09481	February 24, 2000	WIPO	Takeda Chemical Industries, Ltd.	Claims
15.		WO 00/18740	April 6, 2000	WIPO	American Cyanamid Company	
16.		WO 00/24718	May 4, 2000	WIPO	Akzo Nobel N.V.	
17.		WO 01/07432	February 1, 2001	WIPO	Smithkline Beecham P.L.C.	
18.		WO 01/21597	March 29, 2001	WIPO	AstraZeneca AB	
19.		WO 02/056882	July 25, 2002	WIPO	Smithkline Beecham P.L.C.	
20.		WO 02/062767	August 15, 2002	WIPO	Japan Energy Corporation	Yes
21.		WO 02/066445	August 29, 2002	WIPO	Mitsubishi Pharma Corporation	EP 1369418
22.		WO 02/068409	September 6, 2002	WIPO	Merck & Co., Inc.	
23.		WO 02/073235	September 19, 2002	WIPO	Yissum Research Development Company of The Hebrew University Of Jerusalem	
24.		WO 02/076976	October 3, 2002	WIPO	Bayer Corporation	
25.		WO 02/092577	November 21, 2002	WIPO	AstraZeneca AB	
26.		WO 02/092578	November 21, 2002	WIPO	AstraZeneca AB	
27.		WO 02/094790	November 28, 2002	WIPO	Mitsubishi Pharma Corporation	US 2004176361
28.		WO 02/24684	March 28, 2002	WIPO	Smithkline Beecham P.L.C.	
29.		WO 02/30924	April 18, 2002	WIPO	AstraZeneca AB	
30.		WO 02/34744	May 2, 2002	WIPO	AstraZeneca AB	
31.		WO 02/44166	June 6, 2002	WIPO	AstraZeneca AB	
32.		WO 02/48117	June 20, 2002	WIPO	Fujisawa Pharmaceutical Co., Ltd.	
33.		WO 03/049740	June 19, 2003	WIPO	Pfizer Products Inc.	
34.		WO 04/064718	August 5, 2004	WIPO	T.K. Signal Ltd.	
35.		WO 06/092573	September 8, 2006	WIPO	AstraZeneca AB	
36.		WO 06/092574	September 8, 2006	WIPO	AstraZeneca AB	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner

Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5215		Application No. 10/554,202	
RESUBMISSION OF PTO Form 1449 February 27, 2007				Applicants: BRADBURY et al.			
				Filing Date: October 24, 2005		Group Art Unit: 1624	

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
1.	US 4,322,420	March 30, 1982	Kobayashi et al.	514	266.4	September 11, 1979	
2.	US 4,640,920	February 3, 1987	Boyle et al.	514	248	June 13, 1985	
3.	US 5,405,843	April 11, 1995	Fukazawa et al.	514	183	September 9, 1993	
4.	US 5,721,237	February 24, 1998	Myers et al.	514	266.1	June 6, 1995	
5.	US 5,747,498	May 5, 1998	Schnur et al.	514	266.4	May 28, 1996	
6.	US 5,929,080	July 27, 1999	Frost	514	266.4	April 21, 1998	
7.	US 5,962,458	October 5, 1999	Lohmann et al.	514	266.21	December 17, 1996	
8.	US 6,004,967	December 21, 1999	McMahon et al.	514	266.4	September 11, 1997	
9.	US 6,046,206	April 4, 2000	Pamukcu et al.	514	266.21	April 30, 1997	
10.	US 6,117,433	September 12, 2000	Edens et al.	424	400	April 28, 1998	
11.	US 6,313,130	November 6, 2001	Uckun et al.	514	266.24	July 28, 2000	
12.	US 6,326,373	December 4, 2001	Uckun et al.	514	266.1	October 16, 2000	
13.	US 6,384,223	May 7, 2002	Gletsos	544	293	May 4, 2000	

FOREIGN PATENT DOCUMENTS					
Initial	Document No.	Date	Country	Inventor/Assignee	Translation
14.	EP 0 326 330	July 24, 2002	EPA	Dow AgroSciences LLC	
15.	EP 0 520 722	December 27, 1996	EPA	Zeneca Limited	
16.	EP 0 566 226	November 8, 1995	EPA	Zeneca Limited	
17.	EP 0 602 851	October 9, 1996	EPA	Zeneca Limited	
18.	EP 0 787 722	August 6, 1997	EPA	American Cyanamid Company	
19.	EP 0 837 063	April 22, 1998	EPA	Pfizer Inc.	
20.	GB 2,295,387	May 29, 1996	United Kingdom	Glaxo Inc	
21.	JP-08-003144	January 17, 1996	Japan	Chugai Pharmaceut Co Ltd	Abstract
22.	JP-11-189586	July 13, 1999	Japan	Kirin Brewery Co Ltd	Abstract
23.	WO 92/20642	November 26, 1992	WIPO	Rhone-Poulenc Rorer Inter. Inc.	
24.	WO 93/08170	April 29, 1993	WIPO	American Home Products Corp.	
25.	WO 93/17682	September 16, 1993	WIPO	Abbott Laboratories	
26.	WO 95/15758	June 15, 1995	WIPO	Rhone-Poulenc Rorer Pharma. Inc.	
27.	WO 96/09294	March 28, 1996	WIPO	The Wellcome Foundation Limited	
28.	WO 96/15118	May 23, 1996	WIPO	Zeneca Limited	
29.	WO 96/16960	June 6, 1996	WIPO	Zeneca Limited	
30.	WO 96/30347	October 3, 1996	WIPO	Pfizer Inc.	
31.	WO 96/33977	October 31, 1996	WIPO	Zeneca Limited	
32.	WO 96/33978	October 31, 1996	WIPO	Zeneca Limited	
33.	WO 96/33979	October 31, 1996	WIPO	Zeneca Limited	
34.	WO 96/33980	October 31, 1996	WIPO	Zeneca Limited	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Attorney Docket No. 056291-5215		Application No. 10/554,202		
		Applicants: BRADBURY <i>et al.</i>				
		Filing Date: October 24, 2005		Group Art Unit: 1624		
RESUBMISSION OF PFO Form 1449 February 27, 2007						
U.S. PATENT DOCUMENTS						
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Inventor/Assignee	Translation	
35.	WO 96/33981	October 31, 1996	WIPO	Zeneca Limited		
36.	WO 96/39145	December 12, 1996	WIPO	Rhone-Poulenc Rorer Pharmaceuticals Inc.		
37.	WO 97/03069	January 30, 1997	WIPO	Glaxo Group Limited		
38.	WO 97/11692	April 3, 1997	WIPO	Osteoarthritis Sciences, Inc.		
39.	WO 97/13771	April 17, 1997	WIPO	Glaxo Group Limited		
40.	WO 97/22596	June 26, 1997	WIPO	Zeneca-Pharma S.A.		
41.	WO 97/30034	August 21, 1997	WIPO	Zeneca Limited		
42.	WO 97/30035	August 21, 1997	WIPO	Zeneca Pharma S.A.		
43.	WO 97/30034	August 21, 1997	WIPO	Zeneca Limited		
44.	WO 97/30034	October 23, 1997	WIPO	Warner-Lambert Company		
45.	WO 97/30034	October 23, 1997	WIPO	Zeneca Limited		
46.	WO 98/02434	January 22, 1998	WIPO	Glaxo Group Limited		
47.	WO 98/02437	January 22, 1998	WIPO	Glaxo Group Limited		
48.	WO 98/02434	January 22, 1998	WIPO	Glaxo Group Limited		
49.	WO 98/13354	April 2, 1998	WIPO	Zeneca Pharma S.A.		
50.	WO 98/38984	September 11, 1998	WIPO	Sugen, Inc.		
51.	WO 98/50038	November 12, 1998	WIPO	American Cyanamid Company		
52.	WO 98/50370	November 12, 1998	WIPO	Sugen, Inc.		
53.	WO 99/09016	February 25, 1999	WIPO	American Cyanamid Company		
54.	WO 99/24037	May 20, 1999	WIPO	American Cyanamid Company		
55.	WO 99/35132	July 15, 1999	WIPO	Glaxo Group Limited		
56.	WO 99/35146	July 15, 1999	WIPO	Glaxo Group Limited		
57.	WO 99/61428	December 2, 1999	WIPO	Parker Hughes Institute		
58.	WO 00/00202	January 6, 2000	WIPO	Uckun, Fatih, M.		
59.	WO 00/06555	February 10, 2000	WIPO	American Home Products Corporation		
60.	WO 00/10981	March 2, 2000	WIPO	Parker Hughes Institute		
61.	WO 00/20402	April 13, 2000	WIPO	Zeneca Limited		
62.	WO 00/44728	August 3, 2000	WIPO	Pfizer Products Inc.		
63.	WO 00/47212	August 17, 2000	WIPO	Zeneca-Pharma S.A.		
64.	WO 00/51587	September 8, 2000	WIPO	Parker Hughes Institute		
65.	WO 00/51991	September 8, 2000	WIPO	Boehringer Ingelheim Pharma KG		
66.	WO 00/55141	September 21, 2000	WIPO	Boehringer Ingelheim Pharma KG		
67.	WO 00/73260	December 7, 2000	WIPO	Keltech Chiroscience Limited		
68.	WO 01/12227	February 22, 2001	WIPO	American Cyanamid Company		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)						
Examiner			Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5215		Application No. 10/554,202	
RESUBMISSION OF PTO Form 1449 February 27, 2007				Applicants: BRADBURY et al.			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Inventor/Assignee		Translation
	69.	WO 01/21594	March 29, 2001	WIPO	AstraZeneca AB		
	70.	WO 01/21595	March 29, 2001	WIPO	AstraZeneca AB		
	71.	WO 01/32632	May 10, 2001	WIPO	Eli Lilly And Company		
	72.	WO 01/45641	June 28, 2001	WIPO	Parker Hughes Institute		
	73.	WO 01/77085	October 18, 2001	WIPO	AstraZeneca AB		
	74.	WO 01/94341	December 13, 2001	WIPO	AstraZeneca AB		
	75.	WO 01/98277	December 27, 2001	WIPO	Pfizer Products Inc.		
	76.	WO 02/18372	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG		Abstract
	77.	WO 02/41882	May 30, 2002	WIPO	NOVARTIS AG		
	78.	WO 03/040108	May 15, 2003	WIPO	AstraZeneca AB		
	79.	WO 03/040104	May 15, 2003	WIPO	AstraZeneca AB		
	80.	WO 03/082290	October 9, 2003	WIPO	Boehringer Ingelheim Pharma GmbH & Co.		
	81.	WO 03/082831	October 9, 2003	WIPO	AstraZeneca AB		
	82.	WO 2004/006846	January 22, 2004	WIPO	Exelixis, Inc.		
	83.	WO 2004/096226	November 11, 2004	WIPO	AstraZeneca AB		
	84.	WO 2005/012290	November 4, 2004	WIPO	AstraZeneca AB		
	85.	WO 2005/013998	February 17, 2005	WIPO	AstraZeneca AB		
	86.	WO 2005/026150	March 24, 2005	WIPO	AstraZeneca AB		
	87.	WO 2005/026150	March 24, 2005	WIPO	AstraZeneca AB		
	88.	WO 2005/026152	March 24, 2005	WIPO	AstraZeneca AB		
	89.	WO 2005/026156	March 24, 2005	WIPO	AstraZeneca AB		
	90.	WO 2005/026157	March 24, 2005	WIPO	AstraZeneca AB		
	91.	WO 2005/028469	March 31, 2005	WIPO	AstraZeneca AB		
	92.	WO 2005/028470	March 31, 2005	WIPO	AstraZeneca AB		
	93.	WO 2005/030757	April 7, 2005	WIPO	AstraZeneca AB		
	94.	WO 2005/030765	April 7, 2005	WIPO	AstraZeneca AB		
	95.	WO 2005/051923	June 9, 2005	WIPO	AstraZeneca AB		
	96.	WO 2005/075439	August 18, 2005	WIPO	AstraZeneca AB		
	97.	WO 2005/118572	December 15, 2005	WIPO	AstraZeneca AB		
	98.	WO 2006/008526	January 26, 2006	WIPO	AstraZeneca AB		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	99.	Ballard et al. "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 15(19):4226-4229 (2005)					
	100.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket" Bioorg Med Chem Lett. 16(6):1633-1637 (2006)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Attorney Docket No. 056291-5215		Application No. 10/554,202	
RESUBMISSION OF PFO Form 1449 February 27, 2007		Applicants: BRADBURY et al.		Filing Date: October 24, 2005	
				Group Art Unit: 1624	
U.S. PATENT DOCUMENTS					
Initial	Document No.	Date	Name	Class	Sub-Class
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Sub-Class
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
101.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" Bioorg Med Chem Lett. 16(18):4908-4912 (2006)				
102.	Barker et al. "Studies leading to the identification of ZD1839 (Iressa TM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" Bioorganic and Medicinal Chemistry Letters 11(14):1911-1914 (2001)				
104.	Bridges et al. "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor" J. Med. Chem. 39(1):267-276 (1996)				
104.	Denny et al. "Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site for the epidermal growth factor receptor in vitro" Clinical and Experimental Pharmacology and Physiology 23:424-427 (1996)				
105.	Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" Tetrahedron letters 46(43): 7381-7384 (2005)				
106.	Harris et al. "Selective alkylation of a 6,7-dihydroxyquinazoline" Tetrahedron letters 46(45):7715-7719 (2005)				
104.	Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGFR receptor tyrosine kinase inhibitors" Bioorg Med Chem Lett. 16(10):2672-2676 (2006)				
108.	Hennequin et al. "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors" J. Med. Chem. 45 (6):1300 -1312 (2002)				
104.	Rewcastle et al. "Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor" J. Med. Chem. 35:3452-3457 (1995)				
110.	Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002)				
111.	Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997)				
112.	Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998)				
113.	Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001)				
114.	Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003)				
Examiner		Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

RESUBMISSION OF

PTO Form 1449

October 24, 2005

ATTY DOCKET NO.

056291-5215-US

APPLICATION NO

To be assigned

APPLICANT

Robert Hugh BRADBURY et al.

FILING DATE

October 24, 2005

GROUP

To be assigned

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	INVENTOR/ASSIGNEE	TRANSLATION	
						YES	NO
	B01	WO 96/15118	05/1996	PCT	Zeneca Limited		
	B02	WO 03/040108	05/2003	PCT	AstraZeneca AB		
	B03						
	B04						
	B05						

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.